Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Immunomodulator

Therapeutic area intelligence for Immunomodulator with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 10
Catalysts: 0
Companies: 5

Companies

Bristol Myers Squibb →

EUGIA PHARMA →

Zydus Pharmaceuticals →

Assets

Breckenridge →

Bristol-Myers →

Lenalidomide →

POMALIDOMIDE →

Recent signals(10)

RegulatoryJuly 31, 2026

FDA Acceptance of Supplemental Application for Thalidomide by Bristol-Myers

The FDA has accepted a supplemental application for Thalidomide (NDA020785) submitted by Bristol-Myers.

RegulatoryJuly 30, 2026

FDA Accepts Supplemental Application for POMALYST by Bristol

The FDA has accepted a supplemental application for POMALYST (pomalidomide) submitted by Bristol.

RegulatoryJuly 7, 2026

FDA Accepts Supplement Application for Lenalidomide by Zydus Pharmaceuticals

The FDA has accepted a supplemental application for lenalidomide submitted by Zydus Pharmaceuticals.

RegulatoryJuly 7, 2026

EUGIA PHARMA receives AP status for POMALIDOMIDE supplement

EUGIA PHARMA has received an Abbreviated Approval (AP) for a supplement related to POMALIDOMIDE.

RegulatoryJuly 7, 2026

Teva Pharmaceuticals submits supplemental application for Pomalidomide

Teva Pharmaceuticals has submitted a supplemental application for Pomalidomide under ANDA209956.

RegulatoryJuly 6, 2026

FDA Accepts Supplement Application for Lenalidomide by QILU

The FDA has accepted a supplemental application for Lenalidomide submitted by QILU.

RegulatoryJuly 6, 2026

FDA Accepts Supplement Application for Lenalidomide by Apotex

The FDA has accepted a supplemental application for lenalidomide submitted by Apotex.

StrategyJuly 6, 2026

Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval

Lupin has received abbreviated approval for its ANDA214398 application for Lenalidomide.

RegulatoryJuly 6, 2026

FDA Acceptance of POMALIDOMIDE Supplement by Breckenridge

The FDA has accepted the supplemental application for POMALIDOMIDE submitted by Breckenridge.

StrategyJuly 6, 2026

FDA Grants Approval for Thalidomide ANDA213267 by NATCO

The FDA has granted approval for ANDA213267, a generic version of Thalidomide, submitted by NATCO.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.